WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 319540
CAS#: 923981-14-0 (HCl)
Description: Centanafadine, also known as EB-1020, is an adrenergic uptake inhibitor and dopamine uptake inhibitor and serotonin uptake inhibitor. Centanafadine modulates norepinephrine, dopamine and, to a lesser extent, serotonin reuptake in a ratio of 1:6:14, respectively to improve focus, attention and executive function.
MedKoo Cat#: 319540
Name: Centanafadine HCl
CAS#: 923981-14-0 (HCl)
Chemical Formula: C15H16ClN
Molecular Weight: 245.75
Elemental Analysis: C, 73.31; H, 6.56; Cl, 14.43; N, 5.70
Synonym: EB-1020; EB 1020; EB1020; EB-1020 SR; CTN SR; Centanafadine
IUPAC/Chemical Name: (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochoride
InChi Key: ACVMJAJGCQUPKX-LIOBNPLQSA-N
InChi Code: InChI=1S/C15H15N.ClH/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15;/h1-7,14,16H,8-10H2;1H/t14-,15+;/m1./s1
SMILES Code: [H][C@@]12CNC[C@]1(C3=CC=C4C=CC=CC4=C3)C2.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 245.75 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI. Pharmacological
characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020:
implications for treatment of attention-deficit hyperactivity disorder. Synapse.
2012 Jun;66(6):522-32. doi: 10.1002/syn.21538. Epub 2012 Feb 22. PubMed PMID: